Laparoscopic lateral suspension combined with uterosacral ligament folding and shortening versus laparoscopic sacrocolpopexy for the treatment of pelvic organ prolapse: a retrospective cohort study

腹腔镜下侧方悬吊联合子宫骶韧带折叠缩短术与腹腔镜下骶骨阴道固定术治疗盆腔器官脱垂的比较:一项回顾性队列研究

阅读:2

Abstract

BACKGROUND: Pelvic organ prolapse (POP) significantly impacts women's quality of life, with laparoscopic sacrocolpopexy (LSC) considered the gold standard for treatment. However, LSC carries risks of complications, prompting exploration of alternatives. This study compared the efficacy of Laparoscopic Lateral Suspension (LLS) combined with uterosacral ligament folding and shortening (LLS-ULFS) versus LSC for POP treatment. OVERVIEW: A retrospective cohort study included 445 women with POP-Q stage ≥ II (LSC group: n=232; LLS-ULFS group: n=213). Surgical outcomes, complications, and patient-reported outcomes were evaluated over a 2-year follow-up period at Jiangxi Maternal and Child Health Hospital. RESULTS: Both groups achieved high anatomical success rates (LSC vs. LLS-ULFS): apical (96.98% vs. 94.84%), anterior (94.40% vs. 96.24%), and posterior (96.12% vs. 94.37%) compartments (all P>0.05). The LLS-ULFS group demonstrated superior perioperative outcomes: shorter operation time (85 vs. 105 min, P<0.001), reduced blood loss (40 vs. 50 ml, P<0.001), and lower pain scores (VAS: 4 vs. 4, P<0.001). Long-term follow-up showed significantly better patient-reported outcomes in the LLS-ULFS group for PFDI-20, POPDI-6, CRADI-8, and PISQ-12 scores (all P<0.05), indicating improved quality of life and sexual function. Complication rates were comparable (P>0.05). DISCUSSION: LLS-ULFS achieves anatomical success equivalent to LSC while offering advantages in operative efficiency and recovery. The technique's avoidance of presacral dissection likely contributes to reduced pain and complications. CONCLUSION: LLS-ULFS is a viable alternative to LSC, providing comparable anatomical correction with superior perioperative outcomes and enhanced quality of life. Its efficacy supports broader clinical adoption for POP management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。